NICE recommends thalidomide for patients with multiple myeloma

07/27/2011 | Bloomberg

U.K.'s National Institute for Health and Clinical Excellence has recommended the use of Celgene's thalidomide in combination with two other treatments as first-line treatment for patients with multiple myeloma who cannot tolerate high-dose chemotherapy and stem cell transplants. NICE said patients who cannot use thalidomide can use Velcade as an alternative drug.

View Full Article in:

Bloomberg

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Director, Corporate Counsel
Regeneron
Tarrytown, NY